Vaccines and infectious diseases

Velocity is a leader in high-volume vaccine trials and research programs that require access to hard-to-reach patients

Most the world’s leading Sponsors and CROs have made Velocity a strategic partner for their infectious disease research programs. Velocity provides a broad national footprint to support rapid enrollment, even for studies involving sensitive cohorts (e.g., seniors, children, pregnant women, at-risk populations).

Several of Velocity’s principal investigators are also sought after by Sponsors and CROs to guide vaccine-related protocol development. These investigators have had research published in prestigious industry journals, including Vaccine.

Vaccine clinical trials conducted
Investigators supporting vaccine studies
Participants enrolled into vaccine trials

Therapeutic expertise

  • Anthrax
  • Avian Influenza
  • C. difficile (C-diff)
  • Celiac Disease
  • Chikungunya
  • Cytomegalovirus (CMV)
  • Dengue fever
  • Diptheria
  • Ebola
  • Encephalitis
  • HCMV
  • Hepatitis B
  • Herpes
  • Human metapneumovirus (hMPV)
  • Human papillomavirus (HPV)
  • Influenza – H1N1, H5N1, H7N1, and H7N9
  • Lyme disease
  • Meningococcal
  • mRNA vaccines
  • Norovirus
  • Parainfluenza
  • Pediatric influenza
  • Pediatric meningitis
  • Pertussis
  • Plague
  • Pneumococcal
  • Rabies
  • Respiratory syncytial virus (RSV), including maternal and pediatric
  • SARS-CoV-2 (COVID-19)
  • Smallpox
  • Tetanus
  • Type 3 (PIV3)/RSV combo
  • West Nile virus
  • Zika virus
  • Zoster

The proven site network for novel vaccine research programs

Across any indication, including anti-infectives and immunologics, Velocity is prepared to support your research program for a novel vaccine, diagnostic, or combination product.

In-house monitoring, quality assurance, and audit support

PBMC processing capabilities and central laboratory support

Government-funded, Phase 1, and first-in-human trial experience

2020 Vaccine Industry Excellence (ViE) award winner for Best Clinical Trial Site, Best Clinical Trial Network

Let's talk about your next trial